Advertisement

Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics

  • Yuji Kiuchi
  • Toshio Kobayashi
  • Junichi Takeuchi
  • Hiromitu Shimizu
  • Hiroshi Ogata
  • Michio Toru
Article

Summary

[3H]-Flunitrazepam (FNT) binding was measured in the post-mortem brains of 13 chronic schizophrenics and 10 controls whose mean ages and death-to-freezing intervals were the same in each group. The specific binding of [3H]-FNT to the medial frontal cortex, orbitofrontal cortex, orbital cortex, medial and inferior temporal gyri, superior temporal gyrus, cornu Ammonis 1–3 and putamen was significantly higher in schizophrenics than in controls. Specific binding to the eye movement area (frontal eye field), motor cortex, lateral occipitotemporal gyrus, dentate gyrus of the hippocampus and secondary and tertiary visual cortex did not differ in the two groups. Type 1 benzodiazepine (BZ) binding sites in the superior temporal gyrus of schizophrenics, determined from the displacement of [3H]-FNT binding using a triazolopyridazine, CL 218,872 (200nM), were significantly higher than in the control group. The increase in type 2 BZ binding sites was not significant. Antipsychotic or benzodiazepine medication did not appear to affect the results. There were significant correlations between specific [3H]-FNT binding and concentration of GABA (positive) and of glutamic acid (negative), specific [3H]-kainic acid binding (positive), activity of tyrosine hydroxylase (positive), and substance P-like immunoreactivity (positive) in many areas of the brain. The Bmax of [3H]-spiperone binding in the putamen was also correlated positively with specific [3H]-FNT binding. These data suggest that dysfunction of BZ receptors may be involved in the pathogenesis and some symptoms of chronic schizophrenia.

Key words

Chronic schizophrenia Post-mortem brain Specific [3H]-flunitrazepam binding Benzodiazepine receptors Multiple receptors CL 218,872 Neurotransmitters 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arana GW, Ornsteen ML, Kanter F, Friedman HL, Greenblatt DJ, Shader RI (1986) The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 22:77–87Google Scholar
  2. Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK (1986) Diazepam binding inhibitor. Arch Gen Psychiatry 43:1143–1147Google Scholar
  3. Braestrup C, Nielsen M (1981) [3H]Propyl β-carboline-3-carboxylate as a selective radioligand for BZ1 benzodiazepine receptor subclass. J Neurochem 37:333–341Google Scholar
  4. Braestrup C, Nielsen M (1982) Neurotransmitters and CNS disease: Anxiety. Lancet II:1030–1034Google Scholar
  5. Corda MG, Giorgi O, Longoni B, Ongini E, Montaldo S, Biggio G (1988) Preferential affinity of3H-2-oxoquazepam for type I benzodiazepine recognition sites in the human brain. Life Sci 42:189–197Google Scholar
  6. Crawley JN, Marangos PJ, Stivers J, Goodwin FK (1982) Chronic clonazepam administration induces benzodiazepine receptor subsensitivity. Neuropharmacology 21:85–89Google Scholar
  7. DiStefano P, Case KR, Colello GD, Bosmann HB (1979) Increased specific binding of [3H]diazepam in rat brain following chronic diazepam administration. Cell Biol Int Rep 3:163–167Google Scholar
  8. Dorow R, Duka T, Sauerbrey N, Holler L (1987) β-Carbolines: new insights into the clinical pharmacology of benzodiazepine receptor ligands. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 35–51Google Scholar
  9. Ferrero P, Conti-Tronconi B, Guidotti A (1986) DBI, an anxiogenic neuropeptide found in human brain. In: Biggio G, Costa E (eds) GABAergic transmission and anxiety. Raven Press, New York, pp 177–185Google Scholar
  10. Fuxe K, Agnati LF, Bolme P, Hökfelt T, Lidbrink P, Ljungdahl Å, de la Mora MP, Ögren S-O (1975) The possible involvement of GABA mechanisms in the action of benzodiazepines on central catecholamine neurons. In: Costa E, Greengard P (eds) Mechanism of action of benzodiazepines. Raven Press, New York, pp 45–61Google Scholar
  11. Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD, Costa E (1983) Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA 80:3531–3535Google Scholar
  12. Insel TR, Ninan PT, Aloi J, Jimerson DC, Skolnick P, Paul SM (1984) A benzodiazepine receptor-mediated model of anxiety. Arch Gen Psychiatry 41:741–750Google Scholar
  13. Klepner CA, Lippa AS, Benson DI, Sano MC, Beer B (1979) Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem Behav 11:457–462Google Scholar
  14. Lerner Y, Lwow E, Levitin A, Belmaker RH (1979) Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 136:1061–1064Google Scholar
  15. Lippa AS, Critchett D, Sano MC, Klepner CA, Greenblatt EN, Coupet J, Beer B (1979) Benzodiazepine receptors: cellular and behavioral characteristics. Pharmacol Biochem Behav 10:831–843Google Scholar
  16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  17. Mackerer CR, Kochman RL, Bierschenk BA, Bremner SS (1978) The binding of [3H]diazepam to rat brain homogenates. J Pharmacol Exp Ther 206:405–413Google Scholar
  18. Manchon M, Kopp N, Rouzioux JJ, Lecestre D, Deluermoz S, Miachon S (1987) Benzodiazepine receptor and neurotransmitter studies in the brain of suicides. Life Sci 41:2623–2630Google Scholar
  19. Martin IL (1987) The benzodiazepines and their receptors: 25 years of progress. Neuropharmacology 26:957–970Google Scholar
  20. Mendelson WB, Martin JV, Perlis M, Wegner R (1988) Sleep and benzodiazepine receptor sub-types. J Neural Transm 70:329–336Google Scholar
  21. Miller LG, Greenblatt DJ, Shader RI (1987) Benzodiazepine receptor binding: Influence of physiologic and pharmacologic factors. Biopharm Drug Dispos 8:103–114Google Scholar
  22. Möhler H, Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849–851Google Scholar
  23. Möhler H, Okada T, Enna SJ (1978) Benzodiazepine and neurotransmitter receptor binding in rat brain after chronic administration of diazepam or phenobarbital. Brain Res 156:391–395Google Scholar
  24. Niehoff DL, Whitehouse PJ (1983) Multiple benzodiazepine receptors: autoradiographic localization in normal human amygdala. Brain Res 276:237–245Google Scholar
  25. Niles LP, Pulido OM, Pickering DS (1988) Age-related changes in GABA and benzodiazepine receptor binding in rat brain are influenced by sampling time. Prog Neuro-Psychopharmacol Biol Psychiatry 12:337–344Google Scholar
  26. Nishikawa T, Takashima M, Toru M (1983) Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40:245–250Google Scholar
  27. Oakley NR, Jones BJ, Straughan DW (1984) The benzodiazepine receptor ligand CL218,872 has both anxiolytic and sedative properties in rodents. Neuropharmacology 23:797–802Google Scholar
  28. Robertson HA (1979) Benzodiazepine receptors in “emotional” and “non-emotional” mice: comparison of four strains. Eur J Pharmacol 56:163–166Google Scholar
  29. Rupniak NMJ, Prestwich SA, Horton RW, Jenner P, Marsden CD (1987) Alternations in cerebral glutamic acid decarboxylase and3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. J Neural Transm 68:113–125Google Scholar
  30. Saano V (1987) GABA-benzodiazepine receptor complex and drug actions. Med Biol 65:167–173Google Scholar
  31. Singhal RL, Rastogi RB, Lapierre YD (1983) Diazepam potentiates the effect of neuroleptics on behavioural activity as well as dopamine and norepinephrine turnover: Do benzodiazepines have antipsychotic potency? J Neural Transm 56:127–138Google Scholar
  32. Skolnick P, Paul SM (1983) New concepts in the neurobiology of anxiety. J Clin Psychiatry 44:12–19Google Scholar
  33. Snyder SH (1982) Neurotransmitters and CNS disease: Schizophrenia. Lancet II:970–973Google Scholar
  34. Squires RF, Braestrup C (1977) Benzodiazepine receptors in rat brain. Nature 266:732–734Google Scholar
  35. Squires RF, Benson DI, Braestrup C, Coupet J, Klepner CA, Myers V, Beer B (1979) Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav 10:825–830Google Scholar
  36. Tietz EI, Rosenberg HC, Chiu TH (1986) Autoradiographic localization of benzodiazepine receptor downregulation. J Pharmacol Exp Ther 236:284–292Google Scholar
  37. Toru M, Nishikawa T, Mataga N, Takashima M (1982) Dopamine metabolism increases in post-mortem schizophrenic basal ganglia. J Neural Transm 54:181–191Google Scholar
  38. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121–137Google Scholar
  39. Tsang CC, Speeg KV, Wilkinson GR (1982) Aging and benzodiazepine binding in the rat cerebral cortex. Life Sci 30:343–346Google Scholar
  40. Young WS, Niehoff D, Kuhar MJ, Beer B, Lippa AS (1981) Multiple benzodiazepine receptor localization by light microscopic radiohistochemistry. J Pharmacol Exp Ther 216:425–430Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Yuji Kiuchi
    • 1
  • Toshio Kobayashi
    • 1
  • Junichi Takeuchi
    • 1
  • Hiromitu Shimizu
    • 1
  • Hiroshi Ogata
    • 1
  • Michio Toru
    • 1
  1. 1.Department of PsychiatryShinshu University School of MedicineMatsumotoJapan

Personalised recommendations